title: Foam sclerotherapy using polidocanol (aethoxysklerol) for preoperative portal vein embolization in 16 patients.
abstract: OBJECTIVE
  To evaluate the clinical safety and effectiveness of foam sclerotherapy using polidocanol for preoperative portal vein embolization (PVE) before hemihepatectomy of the liver.
  
  
  METHODS
  From March 2006 to October 2008, foam sclerotherapy using polidocanol was performed in 16 patients (male-to-female ratio of 12:4, age range 48-75 years [mean 62]) for PVE. Patients were diagnosed with Klatskin tumor (n = 13), gallbladder (GB) cancer (n = 2), or hepatocellular carcinoma (HCC) (n = 1). The foam was composed of a 1:2:1 ratio of 3% polidocanol (Aethoxysklerol; Kreussler Pharma, Wiesbaden, Germany), room air, and contrast media (Xenetix 350; Guerbet, Aulnay-Sous-Bois, France). The total amount of polidocanol used (2 to 8 mL [mean 4.6]) varied according to the volume of the target portal vein. We calculated the volume of future liver remnant (FLR) before and after PVE and evaluated complications associated with the use of polidocanol foam sclerotherapy for PVE.
  
  
  RESULTS
  Technical success was achieved in all patients. All patients were comfortable throughout the procedure and did not experience pain during sclerotherapy. No periprocedural morbidity or mortality occurred. Patients underwent a liver dynamic computed tomography (CT) scan 2-4 weeks after PVE. FLR increased significantly after PVE using polidocanol foam from 19.3% (range 16-35%) before PVE to 27.8% (range 23-42%) after PVE (p = 0.001). All patients were operable for hemihepatectomy of the liver and achieved effective resection.
  
  
  CONCLUSIONS
  Foam sclerotherapy using polidocanol is clinically safe and effective for preoperative PVE.
authors.affiliation: Department of Radiology and Research Institute of Radiologic Science, Severance Hospital, College of Medicine, University of Yonsei, 143, Shinchon-dong, Seodaemun-gu, Seoul, Republic of Korea.
authors.forename: Sang-Hoon
authors.initials: SH
authors.lastname: Chung
authors.forename: Myung-su
authors.initials: MS
authors.lastname: Lee
authors.forename: Kyung Sik
authors.initials: KS
authors.lastname: Kim
authors.forename: Soon Ii
authors.initials: SI
authors.lastname: Kim
authors.forename: Jong Youn
authors.initials: JY
authors.lastname: Won
authors.forename: Do Yun
authors.initials: DY
authors.lastname: Lee
authors.forename: Kwang-Hun
authors.initials: KH
authors.lastname: Lee
mesh_terms: D000368:Aged; D000792:Angiography; D003287:Contrast Media / Q000627:therapeutic use; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D006801:Humans; D021621:Imaging, Three-Dimensional; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011169:Portal Vein; D011857:Radiographic Image Interpretation, Computer-Assisted; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D015911:Sclerotherapy / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols